Antihypertensive Drugs Market
Antihypertensive Drugs Market - Global Industry Assessment & Forecast
#
Pages:
197
2024
Jul - 2024
VMR-2562
Segments Covered
By
Drug Class Diuretics, ACE Inhibitors, Calcium Channel Blockers, Beta-adrenergic Blockers, Vasodilators, Others
-
By
Type Primary Hypertension, Secondary Hypertension
-
By
End User Retail Pharmacy, Hospital Pharmacy, E-commerce
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2024 |
| Forecast
Years:
|
2025 - 2035 |
 Historical
Years:
|
2019 - 2023 |
 Revenue
2024: |
USD 25.5 Billion |
 Revenue 2035:
|
USD 35.9 Billion |
 Revenue CAGR
(2025 - 2035): |
3.2% |
Fastest Growing Region (2025 -
2035)
|
Asia Pacific |
Largest Region (2024):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
| Sr. No. | Offering | Report Coverage |
| 1. | Market Size | In terms of Revenue (USD Million) |
| 2. | Historic Data | 2019 to 2023 |
| 3. | Forecast Data | 2025 to 2035 |
| 4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
| 5. | Market Attractiveness Analysis | Yes |
| 6. | Segment Analysis | Maximum Segments |
| 7. | Regional Coverage | 5 Regions |
| 8. | Country Coverage | Top 22 Countries |
| 9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
| 10. | Porter’s Five Forces Analysis | Yes. |
| 11. | Value Chain Analysis | Yes |
| 12. | PEST Analysis | Yes |
| 13. | Regulatory Landscape | Yes |
| 14. | Technology Landscape | Yes |
| 15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
| 16. | Top startups to watch out for | Yes |
| 17. | Top 3 Trends to Watch | Yes |
| 18. | Top 3 Strategies Followed by Major Players | Yes |
| 19. | Top 3 Predictions by Vantage Market Research | Yes |
| 20. | Discussion Guide | Yes |
| 21. | Key Primary Respondents - VERBATIM | Yes |
| 22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
| 23. | Others/Miscellaneous | |
Vantage Market
Research | 01-Aug-2024
FAQ
Frequently Asked Question
What is the global demand for Antihypertensive Drugs in terms of revenue?
-
The global Antihypertensive Drugs valued at USD 25.5 Billion in 2024 and is expected to reach USD 35.9 Billion in 2035 growing at a CAGR of 3.2%.
Which are the prominent players in the market?
-
The prominent players in the market are Novartis AG., AstraZeneca plc, Lupin, Daiichi Sankyo Company, Limited, Johnson & Johnson, Pfizer Inc., Sun Pharmaceutical Industries Ltd., SANOFI, Boehringer Ingelheim International GmbH, Merck & Co. Inc.
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 3.2% between 2025 and 2035.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Antihypertensive Drugs include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Antihypertensive Drugs in 2024.
